Stockscreener 앱 받기
0.28
4.86%
-0.0143
시간 외 거래:
.27
-0.01
-3.57%
전일 마감가:
$0.2943
열려 있는:
$0.29
하루 거래량:
1.69M
Relative Volume:
0.51
시가총액:
$28.87M
수익:
$147.75M
순이익/손실:
$-284.23M
주가수익비율:
-0.0956
EPS:
-2.93
순현금흐름:
$-317.54M
1주 성능:
-10.77%
1개월 성능:
-22.31%
6개월 성능:
-23.64%
1년 성능:
-82.28%
1일 변동 폭
$0.27
$0.3235
1주일 범위
$0.27
$0.331
52주 변동 폭
$0.18
$1.74
Fibrogen Inc Stock (FGEN) Company Profile
명칭
Fibrogen Inc
전화
415-978-1200
주소
350 BAY STREET, SAN FRANCISCO, CA
FGEN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
0.28 | 28.87M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-08-08 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-06-26 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-06-26 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-06-26 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-06-26 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-06-02 | 업그레이드 | Stifel | Hold → Buy |
| 2023-01-31 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-01-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-09-22 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-08-20 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-07-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-07-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-04-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-04-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-03-31 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-03-02 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-02-01 | 개시 | H.C. Wainwright | Buy |
| 2020-10-26 | 개시 | Raymond James | Underperform |
| 2020-07-10 | 재개 | Stifel | Buy |
| 2020-05-01 | 개시 | Cowen | Market Perform |
| 2020-04-27 | 개시 | BofA/Merrill | Neutral |
| 2019-05-29 | 재개 | Goldman | Neutral |
| 2019-05-10 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2019-04-12 | 개시 | Piper Jaffray | Neutral |
| 2019-02-11 | 재개 | Stifel | Buy |
| 2018-12-19 | 업그레이드 | Citigroup | Neutral → Buy |
| 2017-08-08 | 재확인 | Leerink Partners | Outperform |
| 2017-08-08 | 재확인 | Stifel | Buy |
| 2017-07-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2017-07-11 | 개시 | Jefferies | Buy |
| 2016-02-11 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2016-01-21 | 개시 | Credit Suisse | Neutral |
| 2015-12-04 | 개시 | Citigroup | Buy |
| 2015-09-23 | 개시 | Lake Street | Hold |
| 2015-07-29 | 개시 | Citigroup | Buy |
| 2015-07-20 | 업그레이드 | Goldman | Neutral → Buy |
| 2014-12-09 | 개시 | Stifel | Buy |
모두보기
Fibrogen Inc 주식(FGEN)의 최신 뉴스
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
FibroGen extends merger option deadline with Fortis - Investing.com Australia
FibroGen extends merger option deadline with Fortis By Investing.com - Investing.com South Africa
Morgan Stanley’s Adam Jonas Is Pounding the Table on This 1 ‘Unique’ Stock - The Globe and Mail
FibroGen reports promising FG-3246 study results for prostate cancer - Investing.com
FibroGen Announces Publication of Results from Phase 1 - GlobeNewswire
1 Top Cryptocurrency to Buy Before It Soars 14,623%, According to Michael Saylor - The Globe and Mail
Fibrogen CEO Wettig Thane buys $50,663 in common stock By Investing.com - Investing.com Australia
Fibrogen CEO Wettig Thane buys $50,663 in common stock - Investing.com India
Fibrogen director James Schoeneck buys $105,040 in stock By Investing.com - Investing.com Canada
In the Red? AstraZeneca Acquires FibroGen, Inc.’s China Subsidiary - Law Street Media
FibroGen, Inc. (NASDAQ:FGEN) Q4 2024 Earnings Call Transcript - Insider Monkey
FibroGen Full Year 2024 Earnings: Beats Expectations - Yahoo
FibroGen Inc (FGEN) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines with ... - Yahoo Finance
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
FibroGen Inc (FGEN) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines with ... By GuruFocus - Investing.com Canada
FibroGen Inc (FGEN) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines with Strategic Initiatives - GuruFocus.com
FibroGen Announces Strategic Sale and Financial Outlook - TipRanks
FibroGen: Q4 Earnings Snapshot - mySA
Earnings call transcript: FibroGen reports Q4 2024 EPS beat, stock dips - Investing.com Canada
Earnings call transcript: FibroGen reports Q4 2024 EPS beat, stock dips By Investing.com - Investing.com South Africa
FibroGen Inc earnings beat by $0.35, revenue fell short of estimates - Investing.com Canada
FibroGen Inc reports results for the quarter ended December 31Earnings Summary - TradingView
FibroGen Inc Reports Q4 2024 Earnings: EPS Loss of $0.08 Beats E - GuruFocus
FIBROGEN Earnings Results: $FGEN Reports Quarterly Earnings - Nasdaq
FIBROGEN INC SEC 10-K Report - TradingView
FibroGen, Inc. Announces Sale of FibroGen China to AstraZeneca for $160 Million and Updates on Clinical Trials - Nasdaq
FibroGen's Strategic $160M China Exit Extends Cash Runway to 2027 Amid Latest Earnings - StockTitan
FIBROGEN Earnings Preview: Recent $FGEN Insider Trading, Hedge Fund Activity, and More - Nasdaq
StockNews.com Initiates Coverage on FibroGen (NASDAQ:FGEN) - Defense World
Weekly CEO Buys Highlight: Camping World, FibroGen - GuruFocus.com
AstraZeneca’s $160 Million Acquisition of FibroGen China - Global Legal Chronicle
Ropes & Gray Advises FibroGen in $160 Million Sale of Fibrogen China to AstraZeneca - Ropes & Gray LLP
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
FibroGen, Inc. to Announce Q4 and Full Year 2024 Financial Results on March 17 - Nasdaq
When Will FibroGen Reveal Its 2024 Performance? Key Date for Investors Announced - StockTitan
FibroGen, Inc. to Host Earnings Call - ACCESS Newswire
FibroGen announces $30M "at the market" equity offering - Investing.com India
FibroGen announces $30M "at the market" equity offering By Investing.com - Investing.com South Africa
FibroGen Says Entered ATM Equity Offering Sales Agreement Relating To Sale From Time To Time Of Shares Of Common Stock - Marketscreener.com
Form 424B5 FIBROGEN INC - StreetInsider.com
Asia Deal Watch: AstraZeneca Buys FibroGen’s Chinese Subsidiary - insights.citeline.com
FibroGen Inc Announces Sale of China Subsidiary to AstraZeneca f - GuruFocus.com
Investor Network: FibroGen, Inc. to Host Earnings Call - ACCESS Newswire
Fibrogen Inc (FGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Fibrogen Inc 주식 (FGEN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Schoeneck James A | Director |
Mar 20 '25 |
Buy |
0.35 |
250,000 |
88,000 |
323,722 |
| Schoeneck James A | Director |
Mar 21 '25 |
Buy |
0.34 |
50,000 |
17,040 |
373,722 |
| Adib Deyaa | Chief Medical Officer |
Jun 12 '24 |
Buy |
1.17 |
22,123 |
25,884 |
82,123 |
10.70%
자본화:
|
볼륨(24시간):